• Explore /
  • Poster
  • / A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

Abstract Poster

Authors

David Gerber

David E. Gerber

The University of Texas Southwestern Medical Center, Dallas, TX

David E. Gerber , Suresh S. Ramalingam , Daniel Morgensztern , Ronan Joseph Kelly , Timothy Francis Burns , Ariel Lopez-Chavez , David R. Spigel , Ahmad Mouhamad Wehbe , Rachel Sorensen , David T. Weaver , Joanna Horobin , Mitchell Keegan , Pier P. Scaglioni , D. Ross Camidge

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT 01951690

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8126)

DOI

10.1200/jco.2014.32.15_suppl.tps8126

Abstract #

TPS8126

Poster Bd #

303A

Abstract Disclosures

Similar Posters

First Author: Joshua E. Reuss

First Author: Daniel Adam Breadner

First Author: Qing Zhou

First Author: Dean Anthony Fennell